NCT07638189

CBD Knee Osteoarthritis Study

Not Yet Recruiting
PHASE2Ages 21+InterventionalTreatment
University of Tennessee
~30 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Cannabidiol (CBD)Castor Oil (Placebo)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Knee Pain
Measured over Day 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
Osteoarthitis
1 sites across 1 states
Tennessee1
  • Karen C Johnson, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Tennessee

Opens a ready-to-send draft in your own email app — review before sending.

  • Knee PainDay 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit

    The investigators will use ecological momentary assessment to collect knee pain scores and develop pain trajectories. A Visual Analog Scale of Self-Reported Pain will be assessed at study visits and up to once a day via text message using the Wong-Baker visual analogue scale. A score of 0 is no pain and a score of 10 is severe pain. Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two). Knee Pain will be assessed at the Screening Visit as an eligibility criteria and at Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74). The Baseline One Visit will occur 2 weeks after the Screening Visit. Change in knee pain scores on the Visual Analog Scale of Self-Reported Pain will be assessed from the Baseline One Visit to the the Follow-up One Visit and from the Baseline Two Visit to the the Follow-up Two Visit.